Ambulero is a spin-out of the University of Miami. It is a first mover in a new field of using gene therapy to provide an adhesion molecule called E-selectin to restore and repair damaged vasculature. Our first indication is a rare vascular disease. Our lead gene therapy AMB-301 received an FDA Orphan Drug Designation and we completed a successful pre-IND meeting. Should clinical testing be successful, Ambulero could be acquired by 2027.